CFO Hoffman to give 2 presentations September 1-2 in Singapore https://informaconnect.com/asia-bio-partnering-forum/speakers/robert-ehoffman/

11AM September 1 in Singapore

Presentation
Cytodyn Inc.
CytoDyn is a clinical-stage biotechnology company advancing leronlimab, a CCR5-targeting monoclonal antibody with potential across multiple solid tumor indications. By blocking CCR5, a key regulator of immune cell trafficking and tumor progression, leronlimab is designed to modulate the tumor microenvironment and enhance anti-tumor immune responses, reducing metastatic potential.

CytoDyn is pursuing a flexible development strategy that includes both monotherapy and its "prime and pair" approach, where leronlimab is used to improve responsiveness to standard-of-care and immuno-oncology combinations. This strategy is supported by translational and clinical data, including initial circulating tumor DNA readouts presented at AACR, with additional updates expected through 2026.

CytoDyn's lead program focuses on metastatic colorectal cancer, where the Phase 2 CLOVER study is evaluating leronlimab with TAS-102 and bevacizumab in heavily pretreated MSS patients. The study has completed enrollment and is showing early promising clinical and biomarker signals.
CytoDyn recently announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insights to support CytoDyn's metastatic colorectal cancer development program.

11AM September 2 in Singapore

Presentation
Oncology: Cytodyn Inc.
CytoDyn is a clinical-stage biotechnology company advancing leronlimab, a CCR5-targeting monoclonal antibody with potential across multiple solid tumor indications. By blocking CCR5, a key regulator of immune cell trafficking and tumor progression, leronlimab is designed to modulate the tumor microenvironment and enhance anti-tumor immune responses, reducing metastatic potential.

CytoDyn is pursuing a flexible development strategy that includes both monotherapy and its "prime and pair" approach, where leronlimab is used to improve responsiveness to standard-of-care and immuno-oncology combinations. This strategy is supported by translational and clinical data, including initial circulating tumor DNA readouts presented at AACR, with additional updates expected through 2026.

CytoDyn's lead program focuses on metastatic colorectal cancer, where the Phase 2 CLOVER study is evaluating leronlimab with TAS-102 and bevacizumab in heavily pretreated MSS patients. The study has completed enrollment and is showing early promising clinical and biomarker signals.

CytoDyn recently announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insights to support CytoDyn's metastatic colorectal cancer development program.

On April 21 we learned in a press release that "CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study". Four 28-day cycles of treatment would be August 11, 2026.

I figure they issued that press release a day or more after they had reached full enrollment, so IMO the last patient of the full enrollment has already completed 4 cycles of treatment. I expect the last patient of the enrollment will have had testing in this week or last, which would measure where things stand after a completed four 28-day cycles of treatment. I expect they just about, or already have 2 post-baseline scans from the full enrollment, which means of course that they already have more scans from the early patients.

This is a point in time I think the data analysis gets really interesting, but I don't expect to hear about it until later.

In my opinion, the databases & spreadsheets will be humming this month at Syneos, CytoDyn, Natera, CreatvBio, and at additional parties who might see data under non-disclosure agreements. I think 2 post-baseline scans from the full enrollment, plus more scans from earlier patients starts to validate trends and starts to validate correlations with the early biomarker data. I think this also marks the time when they might begin to understand how well each dosage level works.

Obviously there is more data to be gathered before the trial ends. All the above is my opinion only.